title: An update in liver transplantation in patients with hepatitis B and hepatitis C.
abstract: Chronic hepatitis C virus (HCV) infection is an epidemic that currently represents the number one indication for liver transplantation (LTx). Hepatitis B virus (HBV) infection is associated with better outcomes following LTx since the advent of hepatitis B immune globulin and lamivudine. The impact of HCV and HBV in LTx is well known. Therapeutic interventions, however, are less standardized and often depend upon institutional protocol. This review article will provide a comprehensive review of the literature and address many issues and complications with transplantation in patients suffering from chronic liver disease as a result of HCV or HBV.
authors.affiliation: ISMETT, University of Pittsburgh, USA.
authors.forename: M
authors.initials: M
authors.lastname: Montalbano
authors.forename: G W
authors.initials: GW
authors.lastname: Neff
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D001663:Bilirubin / Q000097:blood; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000175:diagnosis; D016174:Hepacivirus / Q000235:genetics; D006509:Hepatitis B / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery*; D006515:Hepatitis B virus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D016031:Liver Transplantation; D011182:Postoperative Care; D011300:Preoperative Care; D012008:Recurrence; D012086:Reoperation; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D001663:Bilirubin